Flortaucipir PET Imaging in Subjects With FTD

Phase 1

Completed

• Conditions: Frontotemporal Dementia
• Interventions: Drug: Flortaucipir F18; Procedure: Brain PET scan

• Registration Number: NCT03040713
• Lead Sponsor: Avid Radiopharmaceuticals

Brief Summary

This study is designed to assess the usefulness of flortaucipir in Positron Emission Tomography (PET) imaging for subjects diagnosed with Frontotemporal Dementia (FTD).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-01-31
• Study First Submitted QC: 2017-01-31
• Study First Posted: 2017-02-02
• Study Start: 2017-04-11
• Primary Completion: 2018-10-24
• Study Completion: 2018-10-24
• Results First Submitted: 2020-07-24
• Status Verified: 2020-09
• Results First Submitted QC: 2020-09-03
• Last Update Submitted: 2020-09-03
• Results First Posted: 2020-09-25
• Last Update Posted: 2020-09-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• Subjects diagnosed by a dementia specialist with symptomatic clinical syndromes with expected Frontotemporal Dementia (FTD) pathology will be enrolled. Clinical syndromes associated with FTD pathology include: behavioral-variant FTD, FTD with motor-neuron disease, non-fluent/agrammatic and semantic variants of primary progressive aphasia, progressive supranuclear palsy syndrome and corticobasal syndrome.
• Have provided informed consent or have a legally authorized (LAR) provide consent for study procedures
• Have had volumetric brain MRI obtained in site's companion protocol within one year of enrollment
• Can tolerate PET scan procedures

Read More

Exclusion Criteria

• Have clinically significant cardiac, hepatic, renal, pulmonary, metabolic, or endocrine disturbances that pose potential safety risk
• Have history of risk factors for Torsades de Pointes (TdP) or taking medication known to cause QT prolongation
• Have history of drug or alcohol dependence within the last year
• Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity, or not using reliable contraception
• Have history of relevant severe drug allergy or hypersensitivity
• Have received an investigational medication under FDA IND protocol within 30 days of planned imaging session
• Have received a radiopharmaceutical for imaging/therapy within 24 hours of imaging session
• Possess PET scan evidence of amyloid deposition
• Determined by the investigator to be unsuitable for this type of study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
FTD Subjects	Brain PET scan	Subjects diagnosed by dementia specialist with a clinical Frontotemporal Dementia (FTD) syndrome and expected tau or tar DNA binding protein (TDP)-43 pathology receiving a flortaucipir PET scan
FTD Subjects	Flortaucipir F18	Subjects diagnosed by dementia specialist with a clinical Frontotemporal Dementia (FTD) syndrome and expected tau or tar DNA binding protein (TDP)-43 pathology receiving a flortaucipir PET scan

Primary Outcome Measures

Name	Time	Method
Qualitative Evaluation of Flortaucipir PET Scans	baseline scan	Subject scans were visually evaluated by an expert reader into three groups. Advanced Alzheimer's Disease (AD) scan pattern = In either hemisphere, increased neocortical activity in the parietal/precuneus region(s), or frontal region(s) with increased uptake in the posterolateral temporal (PLT), parietal, or occipital region(s). Moderate AD scan pattern = In either hemisphere, increased neocortical activity limited to the PLT or occipital region(s). Not AD scan pattern = No increased neocortical activity, or increased neocortical activity isolated to the mesial temporal, anterolateral temporal, and/or frontal regions.
Quantitative Evaluation of Flortaucipir PET Scans	baseline scan	Standard Uptake Value Ratio (SUVr) using a weighted cortical average (MUBADA), and individual regions. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

Trial Locations

Locations (3)

Movement Disorder Center, UCSD; 🇺🇸 La Jolla, California, United States

Memory and Aging Center, UCSF; 🇺🇸 San Francisco, California, United States

UT Southwestern Medical Center; 🇺🇸 Dallas, Texas, United States